Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report

We describe a case of coronavirus disease 2019 (COVID-19) in a patient with mixed cellularity classical Hodgkin lymphoma (cHL) undergoing brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy. A 43-year-old man presented to our hospital with a complaint of fever, for which h...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current problems in cancer 2021-12, Vol.45 (6), p.100739-100739, Article 100739
Hauptverfasser:	Fujii, Hiroyuki, Tsuji, Taisuke, Sugitani, Mio, Matsumoto, Yosuke, Yuba, Tatsuya, Tanaka, Shunya, Suga, Yoshifumi, Matsuyama, Aosa, Goda, Shiho, Omura, Ayaka, Shiotsu, Shinsuke, Takumi, Chieko, Ono, Seiko, Hiraoka, Noriya
Format:	Artikel
Sprache:	eng
Schlagworte:	A+AVD therapy (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Adult Alanine - analogs & derivatives Alanine - therapeutic use Amides - therapeutic use Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antiviral Agents - therapeutic use Brentuximab Vedotin - therapeutic use Classical Hodgkin lymphoma COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 Drug Treatment COVID-19 Nucleic Acid Testing Dacarbazine - therapeutic use Disease Progression Doxorubicin - therapeutic use Hodgkin Disease - complications Hodgkin Disease - drug therapy Humans Male Pregnenediones - therapeutic use Pyrazines - therapeutic use Remdesivir, RT-PCR SARS-CoV-2 Time Factors Vinblastine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!